GLP-1s and Heart Health: The SELECT Trial Results Explained

The largest cardiovascular outcomes trial ever conducted for an obesity medication proved that semaglutide reduces heart attack and stroke risk by 20% — even in people without diabetes. Here's why this changes everything.

For decades, weight loss medications faced a credibility problem. Some had been pulled from the market for causing heart valve damage (fenfluramine) or increasing cardiovascular events (sibutramine). The medical community had reason to be cautious. Then came SELECT.

What Was the SELECT Trial?

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was a massive, randomized, double-blind, placebo-controlled trial that enrolled 17,604 adults aged 45 or older. All participants had established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) AND a BMI of 27 or higher — but did NOT have diabetes. NEJM

This design was intentional. The researchers wanted to know: does semaglutide protect the heart independently of any blood sugar benefits? The answer was yes.

Why This Matters So Much

It broke the curse. No weight loss medication had ever shown cardiovascular benefit. SELECT didn't just show safety — it showed active protection. Heart attack risk dropped by 28%. That's a profound shift in how the medical community views these drugs.

It's independent of diabetes. Prior cardiovascular benefits from GLP-1 medications (in trials like SUSTAIN-6 and LEADER) were in patients WITH diabetes. SELECT showed that the heart protection extends to people who "only" have obesity and existing heart disease — a much larger population.

It changes the insurance conversation. When a drug prevents heart attacks and strokes, the cost-benefit math looks very different to insurers. A 20% reduction in MACE translates directly to fewer hospitalizations, fewer procedures, and lower total healthcare spending. This is one of the strongest arguments for broader insurance coverage.

How Does Semaglutide Protect the Heart?

The cardiovascular benefits appear to come from multiple mechanisms working together:

Weight loss reduces the mechanical and metabolic burden on the cardiovascular system — lower blood pressure, improved lipid profiles, reduced cardiac workload.

Anti-inflammatory effects are increasingly recognized as a direct GLP-1 receptor-mediated benefit. The trial showed significant reductions in C-reactive protein (CRP), a key marker of systemic inflammation. Since atherosclerosis is fundamentally an inflammatory disease, this matters enormously.

Metabolic improvements — better insulin sensitivity, reduced triglycerides, improved endothelial function — all contribute to a healthier vascular environment.

Importantly, analysis of the SELECT data suggested that the cardiovascular benefits were not fully explained by weight loss alone. Even after adjusting for the amount of weight lost, semaglutide still showed heart-protective effects — suggesting direct anti-inflammatory and vascular benefits from GLP-1 receptor activation.

What About Tirzepatide?

Eli Lilly is conducting its own cardiovascular outcomes trial (SURPASS-CVOT) for tirzepatide, with results expected in the coming years. Until that data is available, semaglutide remains the only GLP-1 with proven cardiovascular benefit in patients without diabetes. If heart health is a primary consideration, this distinction currently favors semaglutide.

What This Means for You

If you have obesity AND existing cardiovascular disease or high cardiovascular risk, GLP-1 treatment isn't just about the scale. The SELECT data suggests it could meaningfully reduce your risk of a heart attack or stroke — benefits that persist for years with continued treatment.

Talk to your doctor about whether semaglutide makes sense as part of your cardiovascular risk management strategy. This conversation has shifted from "should I try a weight loss drug?" to "should I add a heart-protective medication that also helps with weight?"

Explore GLP-1 Providers

Ready to get started? These verified telehealth providers offer GLP-1 programs with medical oversight and home delivery:

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content or provider selection.